Jie He1, Song Gao, Ming Hu, Diana S-L Chow, Vincent H Tam. 1. Department of Pharmacological and Pharmaceutical Sciences, University of Houston College of Pharmacy, 1441 Moursund Street, Houston, TX, USA.
Abstract
OBJECTIVES: A rapid, sensitive and robust ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method was developed for the quantification of four major polymyxin B components (polymyxin B1, polymyxin B2, polymyxin B3 and isoleucine-polymyxin B1) in serum and epithelial lining fluid (ELF) samples. METHODS: A Waters Acquity UPLC HSS C18 column was used with 0.1% formic acid in water/acetonitrile as mobile phases. Analysis was performed in a positive ionization mode with multiple-reactions monitoring scan type. Five percent trichloroacetic acid was used to precipitate proteins in biological samples and to increase the sensitivity of detection. RESULTS: Our results showed a linear concentration range of 0.0065-3.2 mg/L for all the major polymyxin B components in both serum and ELF, respectively; the interday variation was <10% and the accuracy was 88%-115%. The validated method was used to characterize the pharmacokinetics (serum and ELF) of polymyxin B in mice. CONCLUSIONS: This is the first report, to date, examining the individual pharmacokinetics of various polymyxin B components in mice. Our results revealed no considerable differences in clearances among the components. The limited exposure of polymyxin B in ELF observed was consistent with the less favourable efficacy of polymyxin B reported for the treatment of pulmonary infections. This method can be used to further examine the pharmacokinetics of polymyxin B in a variety of clinical and experimental settings.
OBJECTIVES: A rapid, sensitive and robust ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method was developed for the quantification of four major polymyxin B components (polymyxin B1, polymyxin B2, polymyxin B3 and isoleucine-polymyxin B1) in serum and epithelial lining fluid (ELF) samples. METHODS: A Waters Acquity UPLC HSS C18 column was used with 0.1% formic acid in water/acetonitrile as mobile phases. Analysis was performed in a positive ionization mode with multiple-reactions monitoring scan type. Five percent trichloroacetic acid was used to precipitate proteins in biological samples and to increase the sensitivity of detection. RESULTS: Our results showed a linear concentration range of 0.0065-3.2 mg/L for all the major polymyxin B components in both serum and ELF, respectively; the interday variation was <10% and the accuracy was 88%-115%. The validated method was used to characterize the pharmacokinetics (serum and ELF) of polymyxin B in mice. CONCLUSIONS: This is the first report, to date, examining the individual pharmacokinetics of various polymyxin B components in mice. Our results revealed no considerable differences in clearances among the components. The limited exposure of polymyxin B in ELF observed was consistent with the less favourable efficacy of polymyxin B reported for the treatment of pulmonary infections. This method can be used to further examine the pharmacokinetics of polymyxin B in a variety of clinical and experimental settings.
Authors: Vincent H Tam; Amy N Schilling; Giao Vo; Samer Kabbara; Andrea L Kwa; Nathan P Wiederhold; Russell E Lewis Journal: Antimicrob Agents Chemother Date: 2005-09 Impact factor: 5.191
Authors: Katherine P Holloway; Nadine G Rouphael; Jane B Wells; Mark D King; Henry M Blumberg Journal: Ann Pharmacother Date: 2006-10-03 Impact factor: 3.154
Authors: Cornelia B Landersdorfer; Jiping Wang; Veronika Wirth; Ke Chen; Keith S Kaye; Brian T Tsuji; Jian Li; Roger L Nation Journal: J Antimicrob Chemother Date: 2018-02-01 Impact factor: 5.790
Authors: Dana R Bowers; Henry Cao; Jian Zhou; Kimberly R Ledesma; Dongxu Sun; Olga Lomovskaya; Vincent H Tam Journal: Antimicrob Agents Chemother Date: 2015-02-23 Impact factor: 5.191
Authors: Pooja Manchandani; Jian Zhou; Kimberly R Ledesma; Luan D Truong; Diana S-L Chow; Jason L Eriksen; Vincent H Tam Journal: Antimicrob Agents Chemother Date: 2015-12-07 Impact factor: 5.191
Authors: Sean N Avedissian; Jiajun Liu; Nathaniel J Rhodes; Andrew Lee; Gwendolyn M Pais; Alan R Hauser; Marc H Scheetz Journal: Antibiotics (Basel) Date: 2019-03-22